INTELLIA THERAPEUTICS, INC. (NTLA) Scorecard
- 2026-Q2: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Win; Revenue growth Win; EPS growth Lose.
- 2025-Q4: Total return Lose; Revenue growth Win; EPS growth Lose.
- 2025-Q3: Total return Win; Revenue growth Win; EPS growth Lose.
38/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 6 wins, 6 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q21/3 |
WinNTLA / S&P 31.98% / 15.20% |
LoseNTLA / S&P 12.58% / 15.00% |
LoseNTLA / S&P -28.42% / 50.40% |
| 2026-Q12/3 |
WinNTLA / S&P 42.60% / -4.33% |
WinNTLA / S&P 45.04% / 11.30% |
LoseNTLA / S&P -32.38% / 27.70% |
| 2025-Q41/3 |
LoseNTLA / S&P -47.94% / 2.65% |
WinNTLA / S&P 16.92% / 9.00% |
LoseNTLA / S&P -27.10% / 13.40% |
| 2025-Q32/3 |
WinNTLA / S&P 84.12% / 8.12% |
WinNTLA / S&P 33.52% / 4.61% |
LoseNTLA / S&P -21.69% / 13.45% |
| 2025-Q22/3 |
WinNTLA / S&P 31.93% / 10.94% |
WinNTLA / S&P 14.99% / 4.83% |
LoseNTLA / S&P -14.60% / 10.63% |
| 2025-Q10/3 |
LoseNTLA / S&P -39.02% / -4.27% |
LoseNTLA / S&P -13.37% / 4.98% |
LoseNTLA / S&P -2.61% / 10.57% |
| 2024-Q41/3 |
LoseNTLA / S&P -43.26% / 2.41% |
WinNTLA / S&P 59.55% / 5.25% |
LoseNTLA / S&P -3.14% / 6.15% |
| 2024-Q30/3 |
LoseNTLA / S&P -8.18% / 5.89% |
LoseNTLA / S&P -16.77% / 5.89% |
LoseNTLA / S&P 2.06% / 6.11% |
| 2024-Q20/3 |
LoseNTLA / S&P -18.65% / 4.28% |
LoseNTLA / S&P -13.33% / 5.38% |
LoseNTLA / S&P 0.74% / 5.12% |
| 2024-Q10/3 |
LoseNTLA / S&P -9.77% / 10.56% |
LoseNTLA / S&P -1.63% / 5.71% |
LoseNTLA / S&P -0.19% / 5.59% |
| 2023-Q40/3 |
LoseNTLA / S&P -3.57% / 11.69% |
LoseNTLA / S&P -30.40% / 6.81% |
LoseNTLA / S&P -12.18% / 7.78% |
| 2023-Q30/3 |
LoseNTLA / S&P -22.46% / -3.27% |
LoseNTLA / S&P 0.71% / 7.52% |
LoseNTLA / S&P -9.35% / -5.03% |
| 2023-Q23/3 |
WinNTLA / S&P 9.42% / 8.74% |
WinNTLA / S&P 16.98% / 9.50% |
WinNTLA / S&P 1.49% / -8.57% |
| 2023-Q12/3 |
LoseNTLA / S&P 6.82% / 7.50% |
WinNTLA / S&P 41.24% / 10.77% |
WinNTLA / S&P 6.55% / -15.69% |
| 2022-Q41/3 |
LoseNTLA / S&P -37.65% / 7.56% |
WinNTLA / S&P 57.69% / 11.88% |
LoseNTLA / S&P NTLA unavailable / -17.99% |
| 2022-Q32/3 |
WinNTLA / S&P 8.11% / -4.88% |
WinNTLA / S&P 91.84% / 13.47% |
LoseNTLA / S&P NTLA unavailable / -1.41% |
| 2022-Q20/3 |
LoseNTLA / S&P -28.77% / -16.10% |
LoseNTLA / S&P 8.44% / 13.71% |
LoseNTLA / S&P NTLA unavailable / 11.04% |
| 2022-Q10/3 |
LoseNTLA / S&P -38.54% / -4.60% |
LoseNTLA / S&P -26.52% / 15.97% |
LoseNTLA / S&P NTLA unavailable / 42.23% |
| 2021-Q40/3 |
LoseNTLA / S&P -11.86% / 11.03% |
LoseNTLA / S&P -43.01% / 15.00% |
LoseNTLA / S&P NTLA unavailable / 96.40% |
| 2021-Q30/3 |
LoseNTLA / S&P -17.15% / 0.58% |
LoseNTLA / S&P -57.02% / 10.77% |
LoseNTLA / S&P NTLA unavailable / 69.42% |
| 2021-Q21/3 |
WinNTLA / S&P 101.74% / 8.55% |
LoseNTLA / S&P -17.58% / 6.58% |
LoseNTLA / S&P NTLA unavailable / 51.81% |
| 2021-Q12/3 |
WinNTLA / S&P 47.53% / 6.17% |
WinNTLA / S&P 13.02% / -1.06% |
LoseNTLA / S&P NTLA unavailable / 7.39% |
| 2020-Q42/3 |
WinNTLA / S&P 173.64% / 12.15% |
WinNTLA / S&P 34.55% / -3.72% |
LoseNTLA / S&P NTLA unavailable / -33.42% |
| 2020-Q31/3 |
LoseNTLA / S&P -5.42% / 8.93% |
WinNTLA / S&P 55.65% / -2.04% |
LoseNTLA / S&P NTLA unavailable / -27.10% |
| 2020-Q22/3 |
WinNTLA / S&P 71.87% / 20.54% |
WinNTLA / S&P 37.71% / -0.46% |
LoseNTLA / S&P NTLA unavailable / -27.11% |
| 2020-Q12/3 |
WinNTLA / S&P -16.63% / -19.60% |
WinNTLA / S&P 36.49% / 3.47% |
LoseNTLA / S&P NTLA unavailable / -14.75% |
| 2019-Q42/3 |
WinNTLA / S&P 9.89% / 9.07% |
WinNTLA / S&P 41.63% / 5.36% |
LoseNTLA / S&P NTLA unavailable / 2.99% |
| 2019-Q31/3 |
LoseNTLA / S&P -18.45% / 1.70% |
WinNTLA / S&P 37.04% / 5.02% |
LoseNTLA / S&P NTLA unavailable / 0.21% |
| 2019-Q21/3 |
LoseNTLA / S&P -4.16% / 4.30% |
WinNTLA / S&P 26.46% / 6.64% |
LoseNTLA / S&P NTLA unavailable / 8.65% |
| 2019-Q12/3 |
WinNTLA / S&P 25.13% / 13.65% |
WinNTLA / S&P 22.02% / 8.12% |
LoseNTLA / S&P NTLA unavailable / 14.29% |
| 2018-Q40/3 |
LoseNTLA / S&P -52.31% / -13.52% |
LoseNTLA / S&P NTLA unavailable / 9.05% |
LoseNTLA / S&P NTLA unavailable / 18.23% |
| 2018-Q30/3 |
LoseNTLA / S&P 4.61% / 7.71% |
LoseNTLA / S&P NTLA unavailable / 10.21% |
LoseNTLA / S&P NTLA unavailable / 19.06% |
| 2018-Q21/3 |
WinNTLA / S&P 29.73% / 3.43% |
LoseNTLA / S&P NTLA unavailable / 9.03% |
LoseNTLA / S&P NTLA unavailable / 14.46% |
| 2018-Q11/3 |
WinNTLA / S&P 9.73% / -0.76% |
LoseNTLA / S&P NTLA unavailable / 7.68% |
LoseNTLA / S&P NTLA unavailable / 12.46% |
| 2017-Q40/3 |
LoseNTLA / S&P -22.66% / 6.64% |
LoseNTLA / S&P NTLA unavailable / 7.03% |
LoseNTLA / S&P NTLA unavailable / 13.82% |
| 2017-Q31/3 |
WinNTLA / S&P 55.31% / 4.48% |
LoseNTLA / S&P NTLA unavailable / 5.68% |
LoseNTLA / S&P NTLA unavailable / 17.57% |
| 2017-Q21/3 |
WinNTLA / S&P 13.56% / 3.09% |
LoseNTLA / S&P NTLA unavailable / 4.83% |
LoseNTLA / S&P NTLA unavailable / 17.74% |
| 2017-Q11/3 |
WinNTLA / S&P 7.48% / 6.07% |
LoseNTLA / S&P NTLA unavailable / 3.67% |
LoseNTLA / S&P NTLA unavailable / 13.32% |
| 2016-Q40/3 |
LoseNTLA / S&P -22.97% / 3.82% |
LoseNTLA / S&P NTLA unavailable / 2.09% |
LoseNTLA / S&P NTLA unavailable / 7.05% |
| 2016-Q30/3 |
LoseNTLA / S&P -20.28% / 3.85% |
LoseNTLA / S&P NTLA unavailable / 0.20% |
LoseNTLA / S&P NTLA unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | NTLA total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 15.46% | 20.78% |
| Annualized return | 15.46% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | NTLA total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -92.01% | 83.14% |
| Annualized return | -39.67% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | NTLA total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -34.02% | 319.30% |
| Annualized return | -4.07% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |